Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Thu Jul 06 17:19:57 UTC 2023
by
admin
on
Thu Jul 06 17:19:57 UTC 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
GJD9I3123C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GJD9I3123C
Created by
admin on Thu Jul 06 17:19:57 UTC 2023 , Edited by admin on Thu Jul 06 17:19:57 UTC 2023
|
PRIMARY | |||
|
P21730
Created by
admin on Thu Jul 06 17:19:57 UTC 2023 , Edited by admin on Thu Jul 06 17:19:57 UTC 2023
|
PRIMARY | |||
|
P21730
Created by
admin on Thu Jul 06 17:19:57 UTC 2023 , Edited by admin on Thu Jul 06 17:19:57 UTC 2023
|
PRIMARY |
From | To |
---|---|
1_109 | 1_188 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_5 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INVERSE AGONIST->TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
ANTAGONIST
IC50
|
||
|
INHIBITOR -> TARGET |
IPH5401 is a therapeutic human antibody that specifically binds and blocks C5a receptors (C5aR) expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils. IPH5401 blocks the binding of C5a to C5aR, thereby reducing the accumulation and activation of MDSC and neutrophils in tumors. Treatment with IPH5401 may unleash anti-tumor activities of T cells and NK cells.
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|